Published in BMC Nephrol on September 07, 2012
1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest (2002) 9.50
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int (2007) 3.06
Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension (2008) 2.99
Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int (2008) 2.95
Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis (2008) 2.53
Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis (2009) 2.43
Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int (2005) 2.19
Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int (2010) 2.18
Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A (2008) 2.06
Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol (2006) 2.04
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int (2003) 1.91
1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol (2003) 1.86
Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol (2007) 1.66
Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int (1998) 1.61
Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis (2009) 1.49
A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol (2001) 1.30
Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int (2001) 1.17
Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol (2009) 1.13
Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats. Am J Physiol Renal Physiol (2011) 1.08
Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis (2011) 1.06
Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol Dial Transplant (2009) 1.00
Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D(3) in type 2 diabetic nephropathy in KK-A(y)/Ta mice. Nephron Exp Nephrol (2010) 0.98
No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int (2011) 0.95
Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail (2012) 0.94
Improving global outcomes in mineral and bone disorders. Clin J Am Soc Nephrol (2008) 0.90
Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). Kidney Int Suppl (2004) 0.88
Effects of 22-oxa-calcitriol on podocyte injury in adriamycin-induced nephrosis. Am J Nephrol (2011) 0.84
Effects of 1,25(OH)2D3 on compensatory renal growth in the growing rat. Kidney Int (1991) 0.79
Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia (2005) 0.78
Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease. Nephron Clin Pract (2010) 0.77
Failure of remote ischemic preconditioning to reduce the risk of postoperative acute kidney injury in children undergoing operation for complex congenital heart disease: a randomized single-center study. J Thorac Cardiovasc Surg (2011) 1.58
Airway responses to eucapnic hyperpnea, exercise, and methacholine in elite swimmers. Med Sci Sports Exerc (2008) 1.52
How to start the late referred ESRD patient urgently on chronic APD. Nephrol Dial Transplant (2006) 1.10
Assisted peritoneal dialysis: also for the late referred elderly patient. Perit Dial Int (2008) 1.01
Assisted automated peritoneal dialysis (AAPD) for the functionally dependent and elderly patient. Perit Dial Int (2005) 0.98
The decisive role of free fatty acids for protein conservation during fasting in humans with and without growth hormone. J Clin Endocrinol Metab (2003) 0.91
Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis. Clin Exp Rheumatol (2012) 0.84
Effect of hyperinsulinemia during hemodialysis on the insulin-like growth factor system and inflammatory biomarkers: a randomized open-label crossover study. BMC Nephrol (2013) 0.82
Whole body and forearm substrate metabolism in hyperthyroidism: evidence of increased basal muscle protein breakdown. Am J Physiol Endocrinol Metab (2005) 0.82
Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. Clin Nephrol (2013) 0.81
Increased protein turnover and proteolysis is an early and primary feature of short-term experimental hyperthyroidism in healthy women. J Clin Endocrinol Metab (2008) 0.78
Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism. Eur J Endocrinol (2005) 0.78
Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: a pilot study. Scand J Urol Nephrol (2012) 0.76
Should all adult patients with diarrhoea-associated HUS receive plasma exchange? Lancet (2012) 0.75
The Authors Reply. JACC Cardiovasc Imaging (2016) 0.75
Assisted peritoneal dialysis. Adv Chronic Kidney Dis (2007) 0.75
[Prevention of peritonitis in patients with peritoneal dialysis]. Ugeskr Laeger (2006) 0.75
Impaired postprandial response of the insulin-like growth factor system in maintenance haemodialysis. Clin Endocrinol (Oxf) (2013) 0.75